(Q43491856)

English

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

scientific article published on 4 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

phase III clinical trial

0 references

quality of life

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

6

object named as

David Cella

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

4

object named as

Ethan Basch

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1

object named as

Karim Fizazi

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

2

object named as

Howard I Scher

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

5

object named as

Cora N Sternberg

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

Kurt Miller

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

David Forer

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Mohammad Hirmand

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Johann S de Bono

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

4 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1147-1156

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Osteoblasts in prostate cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer: ESMO Consensus Conference Guidelines 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterising the castration-resistant prostate cancer population: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New and emerging therapies for bone metastases in genitourinary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970303-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70303-1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43491856&oldid=2186354759"